Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

Feb 09

2015

Hua Medicine Announces Positive Phase 1b Results in Diabetes With 4th-Generation Glucokinase Activator, Shows Robust 24-Hour Glucose Control

Following up on its impressive Phase 1a trial data presented at last year's American Diabetes Association conference, Hua Medicine, an innovative, clinical-stage biotechnology company in Shanghai, announced positive results from its recently completed multicenter, multi-dose Phase 1b Trial in Diabetes.

Jan 08

2015

Hua Medicine Raises $25 Million in Series B Financing to Start Phase 2 Trials

Hua Medicine Ltd., an innovative, clinical-stage biotechnology company in Shanghai, announced the closing of a $25 million Series B financing.

Mar 19

2014

Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation & Commences Phase 1b Trials in Diabetes Patients

Hua Medicine Ltd., a leading innovative drug development company in China, announced today the start of multicenter, multi-dose Phase 1b Trials for Diabetes. The company had previously announced positive results from a Phase 1a trial evalsuating HMS5552, a glucokinase activator (GKA) for Type 2 Diabetes, and demonstrated, even at single doses, significant effects in a variety of biochemical diabetes markers such as glucose and glucose-stimulated insulin release (GSIR).

Dec 20

2011

Hua Medicine Licenses Novel Drug Candidate from Roche for Potential Treatment of Diabetes

Hua Medicine, the leading innovative drug development and commercialization company in China, and Roche announced today a licensing agreement for Roche's Glucokinase Activator (GKA) program.

Sep 20

2011

Hua Medicine Lands $50M Financing Commitment for China Biopharmaceutical Innovation, Development and Commercialization

Hua Medicine, the leading innovative drug development and commercialization company in China, announced today that it has secured $50 million in new financing commitments from a prestigious group of US and Chinese healthcare investors, including ARCH Venture Partners, Fidelity Biosesciences, Fidelity Growth Partners Asia, Venrock, Sino-Alliance International Ltd and new investor WuXi PharmaTech Corporate Venture.

Sep 06

2011

Hua Medicine T2D Drug Entered into Clinical Trial in China

Dear Hua Medicine Board Directors, Advisors, Colleagues, Partners and Friends

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.